Two from UK join Caligor Rx in US

Will lead quality assurance and clinical trial supplies

Caligor Rx, a global clinical trial procurement company based in New York, US, has appointed Jess McKenna as head of quality assurance and customer relationships and Jacquelyn May as head of clinical trial supplies. The two women join Caligor Rx, as a team, after having spent five years working together for a UK supplier of clinical trial supplies.

McKenna has a first class degree in Health and Social Care from the Open University in the UK. She was most recently responsible for building a quality assurance department at a supplier of comparator drugs.

May is a registered nurse and joins Caligor Rx after five years in comparator procurement for worldwide clinical trials. She was previously a senior manager in the NHS in the UK.

You may also like

Regulatory
Diversis Capital acquires Caligor Rx

Diversis Capital acquires Caligor Rx

Caligor sources and distributes comparator drugs for clinical trials worldwide from the US and UK
Manufacturing
Why CAPA keeps failing and what strong organisations do differently

Why CAPA keeps failing and what strong organisations do differently

This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
Manufacturing
Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Cloud-based environmental monitoring helps life science organisations establish professional-quality monitoring from day one and scale as requirements evolve
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)

Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)

How a centralised qualification matrix reconciles vendor documentation, integrates risk-based verification and connects commissioning findings with deviation, CAPA and audit-ready evidence
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)

Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)

Documentation Specialist Snehal Godse explains why unit-level FAT and SAT leave critical multivendor interfaces unverified and proposes a risk-based framework to qualify product transfers, control signals, interlocks, sensors and shared utilities
Manufacturing
Streamlining supply chains from clinical trial to commercial scale

Streamlining supply chains from clinical trial to commercial scale

Vetter’s Ayse Hizli discusses commercial supply chain planning, digital visibility, resilience and cold-chain management from clinical development to market launch
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Research grade to GMP: how peptide quality requirements change as development progresses

Research grade to GMP: how peptide quality requirements change as development progresses

This article presents a practical guide to matching peptide characterisation, impurity control, traceability and manufacturing oversight with rising regulatory expectations across preclinical and clinical development
Subscribe now